We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in ...

Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Verona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like ...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent ...

Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...